argenx SE (Euronext & Nasdaq: ARGX) announced on Monday that it will acquire Forte Biosciences (Nasdaq: FBRX) in an all-cash tender offer at $77 per share, representing a total equity value of approximately $2.2 billion. The offer carries a premium of roughly 86% to Forte's volume-weighted average price since the company reported positive Phase 1b vitiligo data on July 9, and 40.5% to the $54.78 closing price on the Friday before announcement.
The acquisition centres on FB102, an anti-CD122 monoclonal antibody that inhibits the interleukin-2 and interleukin-15 signalling pathway implicated in multiple autoimmune conditions. In its Phase 1b vitiligo study, FB102 achieved a 29.6% improvement on the Facial Vitiligo Area Scoring Index. A Phase 2 readout in celiac disease is expected later in 2026. argenx said the clinical validation and differentiated mechanism of action were the primary drivers of its decision to move from strategic investor to outright acquirer.
Boards of both companies have approved the transaction, which is not subject to a financing condition and will be funded from existing cash. Completion is expected in the third quarter of 2026, pending antitrust clearance under the Hart-Scott-Rodino Act and tender of a majority of outstanding Forte shares.
The deal extends argenx's "Vision 2030" strategy to build a leading portfolio in severe autoimmune disease beyond its anchor product efgartigimod, which is approved for generalised myasthenia gravis and immune thrombocytopenia. CEO Karen Massey framed FB102 as fitting the argenx "playbook of compelling biology, strong clinical validation and broad patient need."
For boards evaluating biopharma positioning, the transaction illustrates an accelerating premium-to-data strategy: acquirers are paying large multiples immediately after positive Phase 1b signals rather than waiting for Phase 2 proof-of-concept. The $2.2 billion valuation for a single asset still in early-stage development reflects competitive pressure to secure immunology platform candidates before broader clinical evidence narrows the field.
Source: BioPharma Dive
The Boardroom Report · Published by Tetmo Publishing
Subscribe to The Boardroom Report